Zohar Krivorot

Vertically integrated cannabis producer Cannara Biotech Inc. (TSXV:LOVE) (OTCQB:LOVFF) (FRA: 8CB0) announced its fourth quarter and full fiscal 2024 financial and operating results on Monday ended Aug. 31. The Montreal-based company revealed a 43% year-over-year revenue growth in 2024 to CA$82.2...

Vertically integrated cannabis company Cannara Biotech Inc. (TSXV:LOVE) (OTCQB:LOVFF) (FRA: 8CB0) announced its fiscal third quarter 2024 financial and operating results on Tuesday for the three month period ended May 31, 2024. Zohar Krivorot, Cannara’s president and CEO, praised the company...

Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA: 8CB) released its fiscal third quarter 2023 financial results, revealing net revenue of CA$15.9 million ($12 million), a 57% increase compared to CA$10.1 million in Q3 2022 and 22% increase compared to CA$13 million in Q2 2023. Q3 Fiscal Year...

Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA:8CB) released its fiscal second quarter 2023 financial results, revealing net revenue of CA$13 million ($9.6 million), a 76% increase, compared to Q2 2022, and a 26% increase compared to Q1 2023. Fiscal Q2 2023 Financial Highlights Gross profit...

Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA:8CB) released its fiscal fourth quarter and fiscal year 2022 financial results for the three-month and full year periods ended August 31, 2022, revealing 2022 fiscal year revenue of CA$36 million, ($26.8 million ) a 108% increase compared to 2021...

Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA:8CB), a Quebec-based, vertically integrated producer of cannabis and derivative product offerings, entered into the British Columbia (BC) market. In addition, the company launched two product offerings in the vape and accessory categories. "...

Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA:8CB) fiscal Q3 2022 revenue was $10.1 million, a 36% increase from the previous quarter and a 41% increase compared to Q3 2021. Fiscal Q3 2022 Financial and Operational Highlights Recorded gross profit before fair value adjustments of $3.7...

Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA: 8CB) released its fiscal second quarter 2022 financial and operating results for the three and six-month periods ended February 28, 2022. Fiscal Second Quarter 2022 Financial and Operational Highlights Net loss of $1.14 million compared to...

Vertically integrated cannabis company Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB) released its fourth quarter and fiscal year 2021 financial and operating results on Wednesday with quarterly revenue of CA$6.5 million ($5.12 million), up by 983.33% from CA$600,000 in...

Vertically integrated cannabis company Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB) reported Wednesday that it had generated $7.2 million in the third quarter of 2021, slightly beating previous estimates. The sum, which represents a year-over-year increase of 837%, includes $5.9...

Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB) disclosed Monday it expects to generate roughly $7.1 million in the third quarter of 2021. That's a $5.1 million revenue growth compared to the prior period. The cannabis revenue, net of excise tax from products destined for...

Vertically integrated cannabis company Cannara Biotech Inc. (CSE: LOVE) (OTCQB: LOVFF) disclosed Wednesday it has entered into a proposed stock swap agreement with Global shopCBD.com Inc. and its shareholders. Under the deal, the Vancouver-based company...